Hangzhou Baicreat Pharma-Tech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.
Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Sumitomo Pharma Co. Ltd. is developing the Menin (MEN1)-myeloid/lymphoid or mixed-lineage leukemia (MLL) interaction inhibitor DSP-5336 (enzomenib) for the treatment of MLL-rearranged acute myeloid leukemia.
Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients with HER2-positive cancers, including breast and gastric cancers, is anticipated to begin in the first half of next year.
Oniria Therapeutics SL, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) have partnered to advance ONR-001 for the treatment of colorectal cancer and to prepare it for clinical trials.
Pilatus Biosciences Inc. has obtained IND clearance from the FDA for PLT-012, a first-in-class anti-CD36 monoclonal antibody, for the treatment of solid tumors. Pilatus plans to initiate a first-in-human phase I trial with this metabolic checkpoint antibody in the first quarter of next year.
Nectin-4 is a cell-surface protein that is highly expressed in a variety of solid tumors, including bladder, head and neck, and certain aggressive breast cancers. Its low-level expression in some normal tissues creates a challenge for therapies, which can unintentionally damage healthy cells and trigger severe side effects.
Apollo AP45 Ltd. has described eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitors reported to be useful for the treatment of cancer.
RSS
